Stockreport

Humacyte Highlights Dialysis Access Data; Women Show Strong ATEV Edge, V012 Results Due in June [Yahoo! Finance]

Humacyte, Inc.  (HUMA) 
PDF six-month functional patency of 89% vs 54% for AVF and 12-month secondary patency of 81% vs 48% (joint relative patency 1.65, p Safety profile: no infections or ruptur [Read more]